Aridis Pharmaceuticals
Aridis Pharmaceuticals: A US-based biopharmaceutical firm innovating therapies for infectious diseases and antibody discovery.
Founded
1995Aridis Pharmaceuticals: A US-based biopharmaceutical firm innovating therapies for infectious diseases and antibody discovery.
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company based in San Jose, United States, dedicated to developing novel therapies for infectious diseases. The company focuses on creating first-in-class anti-infectives for life-threatening viral and bacterial respiratory infections. Their innovative platform technology enables the discovery of rare, potent human monoclonal antibodies from patients, addressing global health threats such as antibiotic resistance and viral pandemics.
Aridis Pharmaceuticals has achieved significant milestones, including advancing their treatments for cystic fibrosis and pneumonia to phase 2a clinical trials. Their pioneering work in mining the human immune response for monoclonal antibodies has positioned them as leaders in combating infectious diseases. The company's impact is underscored by its commitment to addressing urgent medical needs with transformative therapies.
Companies similar to Aridis Pharmaceuticals include Idbiologics, Recida Therapeutics, Cidara Therapeutics and Arisan Therapeutics.
Aridis Pharmaceuticals was founded in 1995.
Aridis Pharmaceuticals' headquarters is located in San Jose, CA, US.
Aridis Pharmaceuticals' most recent funding round was for $2.3M (USD) in March 2023.
As of Mar 14, 2023, Aridis Pharmaceuticals has disclosed funding of $81.7M (USD). Undisclosed round amounts are excluded.
Aridis Pharmaceuticals has 37 employees as of Feb 6, 2024.
Arisan Therapeutics
arisanthera.com
